(2006). A: ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood)
(2007). A: ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther
(1996). Acute renal failure.
(2002). Agency: ICH harmonised tripartite guideline; Guideline for good clinical practice E6(R1).
(1964). Association (WMA). Declaration of Helsinki: Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly,
(2002). Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
(2005). CC: Renal failure associated with cancer and its treatment: an update.
(1994). Clearance of circulating endothelin-1 by ETB receptors in rats.
(2010). CN: Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs
(2003). Endothelin inhibition: novel therapy for prostate cancer.
(2009). Endothelin receptors as therapeutic targets in castrationresistant prostate cancer. Eur Urol Suppl
(2003). FDA Guidance for industry: Pharmacokinetics in patients with impaired hepatic function: Study design, data analysis and impact on dosing and labeling.
(1998). FDA Guidance for industry: Pharmacokinetics in patients with impaired renal function: Study design, data analysis and impact on dosing and labeling.
(1976). Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron
(2007). MS: The risk of renal impairment in hormonerefractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer
(2004). PG: Endothelin receptors as novel targets in tumor therapy.
(2010). Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer.
(2009). R: A phase I study of zibotentan (ZD4054) in patients with metastatic, castrateresistant prostate cancer. Invest New Drugs
(1995). Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med
(2009). Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer.
(2007). Swaisland H: Metabolism of [ 14C]-ZD4054 in healthy volunteers.
(1998). T: Endothelininduced apoptosis of A375 human melanoma cells.
(2010). Tabesh M: Role of targeted therapy in the treatment of advanced prostate cancer.
(2009). Taboada MT: In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers. Xenobiotica
(2004). The European Agency for the evaluation of medicinal products: Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function.
(2004). The European Agency for the evaluation of medicinal products: Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function.
(1995). Tozer TN: Clinical Pharmacokinetics: Concepts and Applications.
(1973). Transection of the oesophagus for bleeding oesophageal varices.
(2008). Wülfing P: Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert Rev Anticancer Ther